VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

General Updates | Targeting CD47 in myelofibrosis

Ciro Rinaldi, MD, PhD, Lincoln County Hospital, Lincoln, UK, talks on the role of CD47 and CALR in myelofibrosis (MF) and comments on the potential of targeting CD47 in MF. It has been shown that patients with MF overexpress CD47, an anti-phagocytic receptor, and have a lower expression of CALR, a pro-phagocytic molecule, which results in a dominant anti-phagocytic signal. Recent in vitro assays have shown that treatment with ruxolitinib and magrolimab, a monoclonal antibody against CD47, led to increased cell death. This interview took place virtually.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter